Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,165.08
(
0.80%
)
US TECH 100
26,584.40
(
0.11%
)
Dow Jones
49,247.66
(
-0.13%
)
Brent Oil
101.60
(
0.07%
)
Bitcoin
77,838.82
(
-1.04%
)
News Focus
News Focus
Post# of 257443
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122886
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: oc631 post# 251693

Friday, 05/03/2024 9:54:42 AM

Friday, May 03, 2024 9:54:42 AM

Post# of 257443
In response to your question: 1Q24 PFE Comirnaty sales were $118M US, $236M ex-US; 1Q24 MRNA Spikevax sales were: $100M US; $67M ex-US.

So PFE’s 1Q24 mRNA-COVID-vaccine market share was 54% in the US and 78% ex-US.

I don't want you further upsetting NVAX investors.

LOL

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today